Shortly after failing a Parkinson's disease study, Sanofi's venglustat has missed the mark in another trial in autosomal dominant polycystic kidney disease (ADPKD), whittling down the list
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
